Imatinib Completed Phase 2 Trials for Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Phase Chronic Myelogenous Leukemia / Relapsing Chronic Myelogenous Leukemia Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00049192Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia